Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

Neoplasia (United States)

Volumn 17, Issue 1, 2015, Pages 101-113

  Zhang, Lixin ^a   Ngo, Jason A ^a   Wetzel, Michael D ^a   Marchetti, Dario ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPARANASE; LAPATINIB; RONEPARSTAT; ANTINEOPLASTIC AGENT; BETA GLUCURONIDASE; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RESISTANCE; CLONE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BRAIN TUMOR; BREAST TUMOR; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLUCURONIDASE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964694241     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.11.007     Document Type: Article

References (33)

1. Olayioye, M.A., Neve, R.M., Lane, H.A., Hynes, N.E., The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000), 3159–3167.
2. Cerra, M., Cecco, L., Montella, M., Tuccillo, F., Bonelli, P., Botti, G., Epidermal growth factor receptor in human breast cancer: comparison with steroid receptors and other prognostic factors. Int J Biol Markers 10 (1995), 136–142.
3. Slamon, D.J., Godolphin, W., Jones, L.A., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989), 707–712.
4. Rusnak, D.W., Alligood, K.J., Mullins, R.J., Spehar, G.M., Arenas-Elliott, C., Martin, A.M., et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW57206) in an expanded panel of human normal and tumor cell lines. Cell Prolif 40 (2007), 580–594.
5. Palmieri, D., Bronder, J.L., Herring, J.M., Yoneda, T., Weil, R.J., Stark, A.M., Kurek, R., Vega-Valle, E., Feigenbaum, L., Vortmeyer, A.O., et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67:9 (2007), 4190–4198.
6. Rimawi, M.F., Wiechmann, L.S., Wang, Y.C., Huang, C., Migliaccio, I., Wu, M.F., Gutierrez, C., Hilsenbeck, S.G., Arpino, G., Massarweh, S., et al. Reduced dose and intermittent treatment with lapatinib and tratuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17 (2011), 1351–1361.
7. Gril, B., Palmieri, D., Bronder, J.L., Herring, J.M., Vega-Valle, E., Feigenbaum, Leiwehr D., Steinberg, S.M., Merino, M.J., Gilmer, T.M., Rubin, S.D., et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:15 (2008), 1092–1103.
8. Taskar, K.S., Rudraraju, V., Mittapalli, R.K., Samala, R., Thorshelm, H.R., Lockman, J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastasis of breast cancer. Pharm Res 29 (2012), 770–781.
9. Esteva, F.J., Yu, D., Hung, M.C., Hortobagyi, G.N., Molecular predictor of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7 (2010), 98–107.
10. Fux, L., Ilan, N., Sanderson, R.D., Vlodavsky, I., Heparanase: busy at the cell surface. Trends Biochem Sci 34:10 (2009), 511–519.
11. Ilan, N., Elkin, M., Vlodavsky, I., Regulation, function, and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38:12 (2006), 2018–2039.
12. Reiland, J., Kempf, D., Roy, M., Denkins, Y., Marchetti, D., FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8:7 (2006), 596–606.
13. Reiland, J., Sanderson, R.D., Waguespack, M., Barker, S.A., Long, R., Carson, D.D., Marchetti, D., Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 279:9 (2004), 8047–8055.
14. Zhang, L., Sullivan, P., Suyama, J., Marchetti, D., EGF - induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res 8:2 (2010), 278–290.
15. Marchetti, D., Li, J., Shen, R., Astrocytes contribute to the brain-metastatic specificity of melanoma cell by producing heparanase. Cancer Res 60 (2000), 4767–4770.
16. Murry, B.P., Blust, B.E., Singh, A., Foster, T.P., Marchetti, D., Heparanase mechanisms of melanoma metastatic to the brain: development and use of a brain slice model. J Cell Biochem 97 (2006), 217–225.
17. Cohen, I., Pappo, O., Elkin, M., San, T., Bar-Shavit, R., Hazan, R., et al. Heparanase prompts growth, angiogenesis, and survival of primary breast tumors. Int J Cancer 118 (2006), 1609–1617.
18. Cohen-Kaplan, V., Doweck, I., Naroditsky, I., Vlodavsky, I., IIan, N., Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68:24 (2008), 10077–10085.
19. Naggi, A., Casu, B., Perez, M., Cassinelli, G., Penco, S., Pisano, C., et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol-splitting. J Biol Chem 280 (2005), 12103–12113.
20. Zhang, L., Ridgway, L., Wetzel, M., Ngo, J., Yin, W., Kumar, D., Goodman, J.C., Groves, M., Marchetti, D., The identification and isolation of breast cancer CTCs with brain metastatic competence. Sci Transl Med 5 (2013), 84–93.
21. Zetser, A., Bashenko, Y., Miao, H.-Q., Vlodavsky, I., Ilan, N., Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63 (2003), 7733–7741.
22. Ridgway, L., Wetzel, M.A., Epstein, A., Marchetti, D., Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res 10:6 (2012), 689–702.
23. Ritchie, J.P., Ramani, V.C., Ren, Y., Naggi, A., Torri, G., Casu, B., et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17:6 (2011), 1382–1393.
24. Yoneda, T., Williams, P., Hiraga, T., Niewolna, M., Nishimura, R., A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and brain-seeking clone in vivo and in vitro. J Bone Miner Res 16:8 (2001), 1486–1495.
25. Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 69:17 (2009), 6871–6878.
26. Slack-Davis, J.K., Martin, K.H., Tilghman, R.W., Iwanicki, M., Ung, E.J., Autry, C., et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282 (2007), 14845–14852.
27. Zhang, L., Sullivan, P., Goodman, J.C., Gunaratne, P.H., Marchetti, D., MicroRNA-1258 inhibits breast cancer invasion and metastasis by directly targeting heparanase. Cancer Res - Priority Report, 71, 2011, 645-54.
28. Huang, C., Park, C.C., Hilsenbeck, S.G., Ward, R., Rimawi, M.F., Wang, Y.C., Shou, J., Bissell, M.J., Osborne, K.C., Schiff, R., β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res, 13(4), 2011, R84.
29. Beauvais, D.M., Rapraeger, A.C., Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2:3 (2004), 1–12.
30. Purushothaman, A., Chen, L., Yang, Y., Sanderson, R., Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283:47 (2008), 32628–32636.
31. Lorger, M., Felding-Habermann, B., Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 176:6 (2010), 2958–2971.
32. Nguyen, T.L., Grizzle, W.E., Zhang, K., Hameed, O., Siegal, G.P., Wei, S., Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol 140 (2013), 468–474.
33. Boyango, I., Barash, U., Naroditsky, I., Li, J.P., Hammond, E., Ilan, N., et al. Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res 74:16 (2014), 4504–4514.